Benefits and risks of torasemide in congestive heart failure and essential hypertension

Drug Safety

Volumn 14, Issue 2, 1996, Pages 104-120

  Brater, D Craig ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BUMETANIDE; CIMETIDINE; DIGOXIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDOMETACIN; LOOP DIURETIC AGENT; PROBENECID; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TORASEMIDE;

ARTHRALGIA; ASTHENIA; BODY WEIGHT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DIURESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ESSENTIAL HYPERTENSION; EXERCISE; FATIGUE; HEADACHE; HENLE LOOP; HUMAN; HYPERURICEMIA; HYPOKALEMIA; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG HEMODYNAMICS; MYALGIA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; THORAX PAIN; VERTIGO;

EID: 0030047538     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199614020-00005     Document Type: Review

References (77)

1. Friedel HA, Buckley MM. Torasemide: a review of its pharmacological properties and therapeutic potential. Drugs 1991; 41: 81-103
2. Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121-42
3. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187-92
4. Lohrmann R, Burhoff I, Greger R. Tubular effects of the diuretic torasemide. Cardiology 1994; 84 Suppl. 2: 135-42
5. Giebisch G, Klein-Robbenhaar G, Klein-Robbenhaar J, et al. Renal and extrarenal sites of action of diuretics. Cardiovasc Drugs Ther 1993; 7: 11-21
6. Puschett JB, Jordan LL. Mode of action of torasemide in man. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 3-13
7. Barr WH, Smith HL, Karnes HT, et al. Torasemide dose-proportionality of pharmacokinetics and pharmacodynamics. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 29-37
8. Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991; 41 Suppl. 3: 14-22
9. Scheen AJ. Dose-response curve for torasemide in healthy volunteers. Arzneimittel Forschung 1988; 38: 156-9
10. von Möllendorff E, Neugebaur G. Pharmacokinetics of torsemide in patients with congestive heart failure. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 73-80
11. Kramer WG. Pharmacokinetics and pharmacodynamics of torsemide in congestive heart failure. Cardiology 1994; 84 Suppl. 2: 108-14
12. Delarge J. Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide. Arzneimittel Forschung 1988; 38: 144-50
13. Neugebauer G, Besenfelder E, von Möllendorff E. Pharmacokinetics and metabolism of torasemide in man. Arzneimittel Forschung 1988; 38: 164-6
14. Miners JO, Rees DLP, Valente L, et al. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torasemide metabolism. J Pharmacol Exp Ther 1995; 272: 1076-81
15. Barr WH, Smith H, Karnes HT, et al. Comparison of bioavailability, pharmacokinetics and pharmacodynamics of torasemide in young and elderly healthy volunteers. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 15-28
16. Andreasen F, Hansen U, Husted SE, et al. The pharmacokinetics of furosemide are affected by age. Br J Clin Pharmacol 1983; 16: 391-7
17. Kerremans LM, Tan Y, van Baars H, et al. Furosemide kinetics and dynamics in aged patients. Clin Pharmacol Ther 1983; 34: 181-9
18. Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370-7
19. Silke B. Central hemodynamic effects of diuretic therapy in chronic heart failure. Cardiovasc Drugs Ther 1993; 7: 45-53
20. Silke B. Haemodynamic impact of diuretic therapy in chronic heart failure. Cardiology 1994; 84 Suppl. 2: 115-23
21. Taylor SH. Diuretics in heart failure: some knowns and unknowns. J Cardiovasc Pharmacol 1993; 22 Suppl. 3: S40-S50
22. Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J 1994; 72 Suppl.: S40-S43
23. Brater DC. Pharmacokinetics and pharmacodynamics of torasemide in health and disease. J Cardiovasc Pharm 1994; 22 Suppl. 3: S24-S31
24. Brater DC, Day B, Burdette A, et al. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26: 183-9
25. Vasko MR, Brown-Cartwright D, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985; 102: 314-8
26. Vargo D, Kramer WG, Black PK, et al. The pharmacodynamics of torsemide in patients with congestive heart failure. Clin Pharmacol Ther 1994; 56: 48-54
27. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57: 601-9
28. Cody RJ, Spencer HK, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994; 154: 1905-4
29. Brater DC. Resistance to loop diuretics: why it happens and what to do about it. Drugs 1985; 49: 241-7
30. Stroobandt R, Dodion L, Kesteloot H. Clinical efficacy of torasemide, a new diuretic, in patients with acute heart failure: a double blind comparison with furosemide. Arch Int Pharmacodyn 1982; 260: 151-8
31. Stringer KA, Watson W, Gratton M, et al. Intravenous torsemide as adjunctive therapy in patients with acute pulmonary edema. J Clin Pharmacol 1994; 34: 1083-7
32. Bremner S, Hariman RJI, Kostis JB, et al. Comparison of intravenous torsemide and furosemide in moderate to severe congestive heart failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 49-50
33. Hariman RJ, Bremner S, Louie EK, et al. Dose-response study of intravenous torsemide in congestive heart failure. Am Heart J 1994; 128: 352-7
34. Scheen AJ, Vancrombreucq JC, Delarge J, et al. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 1986; 31 Suppl.: 35-42
35. Langbehn A, Achhammer I, Bölke T. Acute hemodynamic effects of 20 mg torasemide and 20 mg furosemide given intravenously to patients with congestive heart failure. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide; clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 147-55
36. Isbary J, Achhammer I, Wetzels E. The influence of 20 mg torasemide i.v. and 20 mg furosemide i.v. on hemodynamics and diuresis in patients with high grade left heart failure. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 137-46
37. Fiehring H, Achhammer I. Influence of 10 mg torasemide i.v. and 20 mg furosemide i.v. on the intracardiac pressures in patients with heart failure at rest and during exercise. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 97-104
38. Patterson JH, Adams KF, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion Pharmacotherapy 1994; 14: 514-21
39. Mattioli AV, Castellani ET, Casali E. Symptomatic achievements with diuretics in congestive heart failure. Cardiology 1994; 8 Suppl. 2: 131-4
40. Stauch M, Stiehl L. Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide and furosemide in patients with congestive heart failure: a multicenter study. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 121-6
41. Piesche L, Achhammer I, Glocke M, et al. Comparison of torasemide with furosemide in patients with chronic heart failure. In: Puschett JB, Greenberg A, editors. Diuretics II: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1987: 65-7
42. Goebel K-M. Six-week study of torsemide in patients with congestive heart failure. Clin Ther 1993; 15: 1051-9
43. Achhammer I, Häcker W, Glocke M. Efficacy and safety of torasemide in patients with chronic heart failure. Arzneimittel Forschung 1988; 38: 184-7
44. Achhammer I. Long term efficacy and tolerance of torasemide in congestive heart failure. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 126-36
45. Düsing R, Piesche L. Second line therapy of congestive heart failure with torasemide. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 105-20
46. Podszus T, Piesche L. Effect of torasemide on pulmonary and cardiac hemodynamics after oral treatment of chronic heart failure. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 157-66
47. Podszus T, Wagner U, Ploch T. Clinical and haemodynamic effects of long-term treatment with torasemide in congestive heart failure. Cardiology 1994; 84 Suppl. 2: 124-30
48. Lehnert H, Schmitz H, Beyer J, et al. Controlled clinical trial investigating the influence of torasemide and furosemide on carbohydrate metabolism in patients with cardiac failure and concomitant type II diabetes. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 271-4
49. Weinberger MH. Diuretics and their side effects: dilemma in the treatment of hypertension. Hypertension 1988; 11 Suppl. 11: 16-20
50. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 Suppl. 3: 32-9
51. Schmieder RE, Rockstroh JK. Efficacy and tolerance of low-dose loop diuretics in hypertension. Cardiology 1994; 84 Suppl. 2: 36-42
52. Reyes AJ. Renal excretory profiles of loop diuretics: consequences for therapeutic application. J Cardiovasc Pharmacol 1993; 22 Suppl. 3: S11-S23
53. Uchida T, Yamanaga K, Kido H, et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 Suppl. 2: 14-7
54. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145-50
55. Uchida T, Kido H, Yamanaga K, et al. A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery. Prostaglandins Leukot Essent Fatty Acids 1992; 45: 121-4
56. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension: experience with torasemide. Drugs 1991; 41 Suppl. 3: 80-91
57. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7: 63-8
58. Dupont AG, Schoors D, Six RO, et al. Antihypertensive efficacy of low dose torasemide in essential hypertension. J Human Hypertens 1988; 2: 265-8
59. Baumgart P, Walger P, van Eiff M, et al. Long-term efficacy and tolerance of torasemide in essential hypertension. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 169-82
60. Spannbrucker N, Achhammer I, Metz P, et al. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittel Forschung 1988; 38: 190-3
61. Reyes AJ, Chiesa PD, Santucci MR, et al. Hydrochlorothiazide versus a non-diuretic dose of torasemide as once-daily antihypertensive monotherapy in elderly patients. A randomized and double-blind study. In: Kruck F, Mutschler F, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 183-209
62. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertensive patients with 2.5 mg torasemide/day or 50 mg triamterene/25 mg hydrochlorothiazide/day. In: Kruck F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the Second International Symposium on Torasemide; 1988 Oct 21-23; Munich. Progress in pharmacology and clinical pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990: 211-20
63. Data on file, Boehringer Mannheim GmBh, Gaithershurg, MD, USA, 1994
64. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Ann Intern Med 1979; 91: 744-5
65. Gottl KH, Roesch A, Klinke R. Quantitative evaluation of ototoxic side effects of furosemide, piretanide, bumetanide, azosemide and ozolinone in the cat - a new approach to the problem of ototoxicity. Naunyn Schmiedebergs Arch Pharmacol 1985; 331: 275-82
66. Rybak LP, Whitworth C, Scott V. Comparative acute ototoxicity of loop diuretic compounds. Eur Arch Otorhinolaryngol 1991; 246: 353-57
67. Klinke R, Mertens M. Quantitative assessment of torasemide ototoxicity. Arzneimittel Forschung 1988; 38: 153-5
68. Prichard BNC, Owens CWI, Woolf AS. Adverse reactions to diuretics. Eur Heart J 1992; 13 Suppl. G: 96-103
69. Ramsay LE, Yeo WW, Jackson PR. Metabolic effects of diuretics. Cardiology 1994; 84 Suppl. 2: 48-56
70. Herchuelz, A, Derenne F, Deger F, et al. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance. J Pharmacol Exp Ther 1989; 248: 1175-81
71. van Ganse E, Douchamps J, Deger F, et al. Failure of indomethacin to impair the diuretic and natiuretic effects of the loop diuretic torasemide in healthy volunteers. Eur J Clin Pharmacol 1986; 31 Suppl.: 43-7
72. Kramer BK, Ress KM, von Mollendorf E. Effect of the loop diuretic torasemide on serum level and renal elimination of digoxin. In: Puschett JB, Greenberg A, editors. Diuretics III: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1990: 66-8
73. Kramer WG. Lack of effect of cimetidine on torasemide pharmacokinetics and pharmacodynamics in healthy subjects. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 361-4
74. Piesche L, Bölke T. Comparative clinical trial investigating possible interactions of torasemide (20 mg o.d.) or furosemide (40 mg o.d.) with phenprocoumon in patients with congestive heart failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 267-70
75. Kramer WG. Effect of food on the pharmacokinetics and pharmacodynamics of torsemide. Am J Ther 1995; 2: 499-503
76. Moser M. Diuretics and cardiovascular risk factors. Eur Heart J 1992; 13 Suppl. G: 72-80
77. Moser M. Effects of diuretics on morbidity and mortality in the treatment of hypertension. Cardiology 1994; 84 Suppl. 2: 27-35